Global and glucocorticoid receptor gene-specific (NR3C1) DNA methylation analysis in patients with cannabinoid or synthetic cannabinoid use disorder

Basit Öğe Kaydı
dc.authoridAytac, Hasan Mervan / 0000-0002-1053-6808
dc.contributor.authorPehlivan, Sacide
dc.contributor.authorAytac, Hasan Mervan
dc.contributor.authorAydin, Pinar Cetinay
dc.contributor.authorNursal, Ayse Feyda
dc.contributor.authorPehlivan, Mustafa
dc.date.accessioned2021-11-01T15:06:09Z
dc.date.available2021-11-01T15:06:09Z
dc.date.issued2021
dc.department[Belirlenecek]
dc.description.abstractThis study investigates the relationship between cannabinoid use disorder (CUD) or synthetic cannabinoid use disorder (SCUD) and the global methylation, methylation of NR3C1 gene promotor, and NR3C1 BclI poly-morphism, considering clinical parameters. Based on the DSM-5 criteria, 172 SCUD patients? and 44 CUD pa-tients? diagnoses were confirmed with a positive urine test; 88 healthy volunteers were also included in the study. Global DNA methylation was measured using a 5-methylcytosine (5-mC) DNA ELISA Kit. Methylation-specific PCR was used to identify the methylation of the NR3C1 gene. The analysis of the BclI polymorphism of the NR3C1 gene was evaluated by using the PCR-RFLP. Our results demonstrated that the mean of 5-mC percentages of SCUD patients differed significantly from those of the control group. When comparing NR3C1 gene methyl-ation and clinical parameters due to NR3C1 genotype distribution in patients, the genotype distribution was significantly different between the groups, due to the former polysubstance abuse. Additionally, there was a significantly positive correlation between the 5-mC percentages of SCUD patients and the reported durations of their disorders. In summary, whereas global DNA methylation may be associated with SCUD, the methylation of the NR3C1 gene and NR3C1 BclI polymorphism were not related to CUD or SCUD.
dc.description.sponsorshipIstanbul University BAP-YOPIstanbul University [TYO-2019-32579]en_US
dc.description.sponsorshipThis study was supported by the Istanbul University BAP-YOP (TYO-2019-32579) program.en_US
dc.identifier.doi10.1016/j.psychres.2021.113774
dc.identifier.issn0165-1781
dc.identifier.issn1872-7123
dc.identifier.pmid33556690
dc.identifier.scopus2-s2.0-85100380991
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.psychres.2021.113774
dc.identifier.urihttps://hdl.handle.net/11491/7504
dc.identifier.volume298en_US
dc.identifier.wosWOS:000634552600007
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherElsevier Ireland Ltd
dc.relation.ispartofPsychiatry Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectSynthetic cannabinoid use disorderen_US
dc.subjectCannabinoid use disorderen_US
dc.subjectGlobal DNA methylationen_US
dc.subjectNR3C1-specific DNA methylationen_US
dc.subjectSingle nucleotide polymorphismen_US
dc.titleGlobal and glucocorticoid receptor gene-specific (NR3C1) DNA methylation analysis in patients with cannabinoid or synthetic cannabinoid use disorder
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu